RETRA increases β-galactosidase activity only in cancer cells carrying mutant p53 (p53R248Q, p53R280L, and p53G266E) with increased mRNA expression of p21 and PUMA, but fails to do so in cells wild type or null for p53. Here, TP53 is linked to cancer.